⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769901 | 0.84 | — | — | |
| SCHEMBL631999 | 0.82 | — | — | |
| SCHEMBL668387 | 0.82 | — | — | |
| SCHEMBL3111009 | 0.79 | TSHR (0.32) | — | |
| SCHEMBL473625 | 0.78 | — | — | |
| SCHEMBL437738 | 0.76 | TSHR (0.35) | — | |
| SCHEMBL343237 | 0.76 | — | — | |
| SCHEMBL5423967 | 0.76 | TSHR (0.41) | — | |
| SCHEMBL856391 | 0.76 | — | — | |
| SCHEMBL303389 | 0.76 | TSHR (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386511-B2 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | PTC THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | disclosed |
| US-11638706-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11608501-B2 | Methods for modifying RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-11382918-B2 | Methods for treating Huntington's Disease | PTC THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210275526-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3848035-A1 | 1,4-DISUBSTITUTED PYRIDAZINE COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3386511-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2021-05-12 | — | — | EP | disclosed |
| EP-3644996-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200113904-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190000844-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2019005980-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005993-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |